All News

A poster presented at AMCP Nexus 2023 reported that payers believe implementing the Inflation Reduction Act (IRA) will impact Medicare Part D plans financially.

FluMist Quadrivalent could become the first self-administered flu vaccine in the United States; the American Society of Reproductive Medicine updates its definition of infertility to be more inclusive; the Environmental Protection Agency moves to ban the use of a cancer-causing chemical .

Individuals with genetic syndromes or neurodevelopmental conditions experienced shorter and poorer quality sleep, while those with heterogeneous intellectual disabilities had comparable duration but lower quality to controls.

Patients with heart failure with preserved ejection fraction (HFpEF) may experience worsened exercise tolerance if they also have anemia.

Researchers evaluated the risk of hospitalization for severe flare-ups after vaccination in patients with multiple sclerosis (MS).

MARIPOSA demonstrated the combination reduced risk of progression or death by 30% compared with osimertinib. MARIPOSA-2 found amivantamab plus chemotherapy and amivantamab plus chemotherapy and lazertinib also improved progression-free survival (PFS) over chemotherapy after progression on osimertinib.

At the 2023 COA Payer Exchange Summit being held October 23-24 in Reston, Virginia, Lalan Wilfong, MD, US Oncology Network, emphasizes the importance of oncology care equity, ensuring continuity of care, and enhancing care coordination.

Datopotamab deruxtecan not only demonstrated a statistically significant improvement over chemotherapy for breast cancer and docetaxel for non–small cell lung cancer (NSCLC), but the intervention therapy had less toxicity.

Psoriasis status from time of diagnosis to initiation of current treatment was less favorable for patients with mild psoriasis compared with moderate psoriasis, according to one study.

The first-of-its-kind Aurora EV-ICD system offers a single-device, single procedure with a lead placed outside of the heart and veins.

Medicare Advantage (MA) plans pose financial challenges for small rural hospitals; 2 bans proposed in Texas would prohibit transportation for abortion procedures; delays in reauthorizing US President's Emergency Plan for AIDS Relief (PEPFAR) risk the program’s effectiveness and integrity.

A pooled analysis with nearly 3 years of follow-up showed better outcomes when zanubrutinib was given in the second line vs later lines of therapy in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.

Recognizing that skin diseases such as atopic dermatitis, psoriasis, and hidradenitis suppurativa present differently in skin of color can prevent delays in diagnosis and treatment, explained James Song, MD, director of clinical research and associate chief medical officer at Frontier Dermatology.

Clinical-grade, expert-supported natural language processing (NLP) is valuable to payers and providers when exchanging patient information through continuity-of-care documents.

Enfortumab vedotin plus pembrolizumab not only beat chemotherapy in the first-line setting for locally advanced metastatic urothelial cancer for the first time in decades, but it nearly doubled progression-free survival and overall survival vs chemotherapy.

Posters presented at Fall Clinical Dermatology 2023 found that dupilumab had effective and safe results when received in a 5-year period for atopic dermatitis.

A panel discussion that took place at the 2023 Fall Clinical Dermatology Conference focused on the importance of information to treat both vitiligo and atopic dermatitis.

Regardless of presence of brain metastases, patients with HER2-mutant (HER2m) non–small cell lung cancer (NSCLC) showed systemic responses to trastuzumab deruxtecan. In addition, the therapy showed intracranial efficacy to reduce the size of brain metastases.

The results of CheckMate 77T showcase the improved event-free survival for patients with resectable non–small cell lung cancer who receive nivolumab in both the neoadjuvant and adjuvant setting and may have practice-changing implications.

Lauren Miller, PA-C, kicked off the inaugural 2023 Inflammatory Disease Summit by discussing the psychosocial impacts related to atopic dermatitis, psoriasis, and hidradenitis suppurativa.

Phase 3 data presented at ISPAD found that teplizumab-mzwv (Tzield) was better at slowing the progression of type 1 diabetes (T1D) in newly diagnosed children and adolescents.

With stringent criteria, randomized controlled trials are the cornerstone of cancer intervention research, but the result is they do not represent the majority of patients, which leads to a gap between the efficacy seen in trials and the effectiveness in the real-world setting.

Researchers noted that adverse pregnancy outcomes are more of an indicator of pre-pregnancy cardiovascular risk rather than a primary cause of postpartum risk.

No differences in mammography completion were observed between an automated opt-out vs an opt-in patient outreach program for breast cancer screening, according to a randomized controlled trial. However, differences in administration burden between programs could lead clinics to prefer one over the other.

Patients with alopecia areata found effective treatment with baricitinib, which had long-term efficacy and positive results.

A panel hosted at Fall Clinical Dermatology 2023 highlighted how dermatologists can help to address acne and psoriasis in their patients.

RGX-202, a gene therapy for Duchenne muscular dystrophy, was well tolerated with no therapy-related serious adverse effects in 3 patients who received the level 1 dosage.

With the approval, zilucoplan becomes the first once-daily subcutaneous complement C5 inhibitor available for adults with generalized myasthenia gravis.

Adding pembrolizumab to combination of trastuzumab and chemotherapy improved progression-free survival vs placebo plus trastuzumab and chemotherapy in the first-line treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer.